减重手术患者治疗性抗凝的管理
本研究回顾性分析2012年至2019年间2933例减重手术患者,其中64例围术期接受治疗性抗凝。结果显示出血事件发生率为6.2%(4例),均发生在术后72小时内且抗凝已重启,无血栓并发症。结论认为减重手术在该人群可安全实施,但围术期出血风险较高,术中精细止血是关键。
要点
- 减重手术患者围术期治疗性抗凝者出血风险增加,需警惕术后72小时内出血。
- 出血事件均发生在抗凝重启后,平均重启时间为术后1.25天。
- 术中精细止血是预防出血并发症的最重要环节。
核心结论
- 减重手术可在治疗性抗凝患者中安全实施,但围术期出血并发症风险较高。
研究设计与样本
- 回顾性分析单机构数据库2012年1月1日至2019年8月31日2933例减重手术,筛选64例围术期治疗性抗凝患者。
主要发现
- 64例治疗性抗凝患者中4例(6.2%)发生出血事件,均为术前使用华法林者。
- 3例为腔外出血,1例为腔内出血,所有出血事件均发生在术后72小时内。
- 4例出血患者均在出血显现前已重启抗凝,平均重启时间为术后1.25天。
- 出血与非出血患者术前停药时间无显著差异,治疗性桥接治疗未增加出血风险。
- 抗凝中断期间无血栓并发症发生。
临床怎么用
- 对减重手术合并治疗性抗凝患者,应重视术中精细止血以预防出血并发症。
- 术后重启抗凝需个体化评估,密切监测出血征象,尤其术后72小时内。
局限性
- 回顾性单中心设计,样本量较小(64例抗凝患者),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients that undergo bariatric surgery are at risk of bleeding. Some obesity-related comorbidities including venous thromboembolism and heart disease can often require therapeutic anticoagulation. Previous small institutional studies have demonstrated that bariatric surgery can be performed in this patient population. This study attempts to identify best practices in stopping and restarting therapeutic anticoagulation in patients undergoing bariatric surgery. METHODS: A retrospective analysis was completed of our institution's database using anticoagulant medications to identify patients on therapeutic anticoagulation. Patients not on therapeutic anticoagulation were excluded, as well as patients that were started on therapeutic anticoagulation only in the post-operative period or those whose anticoagulation was stopped and not restarted. Indications for anticoagulation were recorded, as well as patient demographics and comorbid conditions. The patient chart was examined for when anticoagulation was stopped before surgery, when it was restarted after surgery, and whether or not the patient was therapeutically bridged. Baseline and post-operative hemoglobin values were recorded, as well as bleeding events, transfusions, reoperation, length of stay, and readmissions. Binary variables were compared across groups using Chi-square and Fisher's exact tests, and continuous variables were analyzed using T test. RESULTS: There were 2933 bariatric operations performed between January 1, 2012 and August 31, 2019. Of these patients, 64 were on therapeutic anticoagulation before and after the operation for one or more indications, including history of VTE (39), atrial fibrillation (27), clotting disorder (6), ventricular assist device (5), previous PCI (4), or mechanical valve (2). There were 4 (6.2%) patients that experienced bleeding events. All four patients were on Coumadin pre-operatively. Three patients experienced extraluminal bleeding, and one patient had intraluminal bleeding, and all events occurred within 72 h of the operation. All four patients had their anticoagulation restarted prior to the bleeding event becoming evident, with anticoagulation in these patients restarted an average of 1.25 days after surgery. There were no conditions that predisposed a patient to bleeding. There was no significant difference in amount of time anticoagulation was stopped before surgery in bleeding versus non-bleeding patients, and there appeared to be no increased risk of bleeding in patients that were on therapeutic bridging therapy. There were no thrombotic complications from the interruption in anticoagulation therapy. CONCLUSIONS: Bariatric surgery can be safely performed in patients on therapeutic anticoagulation, though this population is at greater risk for bleeding complications in the perioperative period. Meticulous hemostasis in the operating room is the most important aspect of preventing bleeding complications.
引用
- Shea B, Motamedi SMK, Mustafa R, et al. (S029) Managing therapeutic anticoagulation in bariatric surgery patients. Surg Endosc. 2020. PMID: 32909204. doi:10.1007/s00464-020-07958-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。